Hiroaki Asai

514 total citations
30 papers, 359 citations indexed

About

Hiroaki Asai is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Hiroaki Asai has authored 30 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Molecular Biology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Hiroaki Asai's work include CAR-T cell therapy research (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and Virus-based gene therapy research (4 papers). Hiroaki Asai is often cited by papers focused on CAR-T cell therapy research (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and Virus-based gene therapy research (4 papers). Hiroaki Asai collaborates with scholars based in Japan, Canada and United States. Hiroaki Asai's co-authors include Masaki Yasukawa, Kengo Takeuchi, Kiyohiko Hatake, Daisuke Ennishi, Junichi Mineno, Sachiko Okamoto, Y. Terui, Hiroshi Shiku, Masaru Yokoyama and Kiyotaka Kuzushima and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Hiroaki Asai

25 papers receiving 351 citations

Peers

Countries citing papers authored by Hiroaki Asai

Since Specialization

Citations

This map shows the geographic impact of Hiroaki Asai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Asai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Asai more than expected).

Fields of papers citing papers by Hiroaki Asai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Asai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Asai. The network helps show where Hiroaki Asai may publish in the future.

Co-authorship network of co-authors of Hiroaki Asai

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Asai. A scholar is included among the top collaborators of Hiroaki Asai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Asai. Hiroaki Asai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P33-7 Two patients with DLBCL who developed aortitis following pegfilgrastim administration during chemoimmunotherapy 2023 ·Annals of Oncology ·(unknown), Hiroaki Asai, (unknown), (unknown), (unknown), (unknown), (unknown), Yuko Ishihara, Yuko Mishima, Dai Maruyama	0
2	Micelle‐crosslinked hydrogels with stretchable, self‐healing, and selectively adhesive properties: Random copolymers work as dynamic yet self‐sorting domains 2023 ·SHILAP Revista de lepidopterología ·Hiroaki Asai, (unknown), Mikihito Takenaka, S. Takata, Kosuke Hiroi, Makoto Ouchi, Takaya Terashima	13
3	Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy 2023 ·Scientific Reports ·(unknown), Noriko Nishimura, Yuko Mishima, Yuko Ishihara, Hiroaki Asai, (unknown), (unknown), (unknown), (unknown), (unknown), Kengo Takeuchi, Takashi Terauchi, Dai Maruyama	4
4	Better Peptides via Chemical Glycosylation: Somatostatin Analogues Having a Human Complex‐Type N‐Glycan with Improved Drug Properties 2023 ·Chemistry - A European Journal ·Hirofumi Ochiai, Taiji Shimoda, (unknown), (unknown), Kazuyuki Ishii, Kenta Yoshida, Katsunari Tezuka, (unknown), (unknown), Hiroaki Asai, Akio Kanatani, Yuji Nishiuchi	3
5	Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy 2019 ·Scientific Reports ·(unknown), Toshiki Ochi, Kazushi Tanimoto, Hiroaki Asai, Takashi Saitou, Hiroshi Fujiwara, Takeshi Imamura, Katsuto Takenaka, Masaki Yasukawa	25
6	Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma 2018 ·Cancer Science ·Shinsuke Iida, Masashi Wakabayashi, Kunihiro Tsukasaki, Ken‐ichi Miyamoto, Dai Maruyama, Kazuhito Yamamoto, Y Takatsuka, Shigeru Kusumoto, Junya Kuroda, Kiyoshi Ando, Yoshitaka Kikukawa, Yasufumi Masaki, Miki Kobayashi, Ichiro Hanamura, Hiroaki Asai, Hirokazu Nagai, Kazuyuki Shimada, Norifumi Tsukamoto, (unknown), Kensei Tobinai	5
7	Successful treatment of large transformed mycosis fungoides with gemcitabine monotherapy 2018 ·Annals of Oncology ·Hiroaki Asai, (unknown), (unknown), Toshiki Ochi, Kazushi Tanimoto, Jun Yamanouchi, Taichi Azuma, Hiroshi Fujiwara, Takaaki Hato, Masaki Yasukawa, Yoshihiro Yakushijin	0
8	Biopharmaceutical Discovery by Organic Synthesis 2017 ·Trends in Glycoscience and Glycotechnology ·Hiroaki Asai, Hirofumi Ochiai, (unknown)	0
9	Antileukemia multifunctionality of CD4+ T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer 2015 ·Leukemia ·Hiroshi Fujiwara, Toshiki Ochi, Fumihiro Ochi, Yuji Miyazaki, Hiroaki Asai, Miwako Narita, Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroshi Shiku, Masaki Yasukawa	12
10	Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy 2014 ·Cancer Immunology Research ·Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai, (unknown), Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroshi Shiku, J. Carl Barrett, Eiichi Ishii, Masaki Yasukawa	34
11	Adoptive transfer of genetically engineered WT1-specific cytotoxic T lymphocytes does not induce renal injury 2014 ·Journal of Hematology & Oncology ·Hiroaki Asai, Hiroshi Fujiwara, Sohei Kitazawa, Naoto Kobayashi, Toshiki Ochi, (unknown), Fumihiro Ochi, Yoshiki Akatsuka, Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroaki Ikeda, Hiroshi Shiku, Masaki Yasukawa	3
12	Co-Introduced Functional CCR2 Potentiates In Vivo Anti-Lung Cancer Functionality Mediated by T Cells Double Gene-Modified to Express WT1-Specific T-Cell Receptor 2013 ·PLoS ONE ·Hiroaki Asai, Hiroshi Fujiwara, Jun An, Toshiki Ochi, (unknown), Kozo Nagai, Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroshi Shiku, Hirofumi Inoue, Masaki Yasukawa	37
13	Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma 2012 ·Oncology Letters ·Yuichiro Tada, Shin-ichiro Maruya, Takashi Saotome, Kouki Miura, Tatsuo Masubuchi, Chihiro Fushimi, Isaku Okamoto, (unknown), Shuhei Yamada, Hiroaki Asai, (unknown)	1
14	[Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer]. 2011 ·PubMed ·Hiroaki Asai, Eiji Shinozaki, Akira Nozaki, (unknown), Mitsukuni Suenaga, (unknown), Keisho Chìn, Nobuyuki Mizunuma, Masaki Yasukawa, Kiyohiko Hatake	1
15	An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy 2009 ·Clinical Cancer Research ·Yuji Mishima, Natsuhiko Sugimura, (unknown), Yasuhito Terui, Kengo Takeuchi, (unknown), Daisuke Ennishi, Hiroaki Asai, Masahiro Yokoyama, Kiyotsugu Kojima, Kiyohiko Hatake	13
16	Factors Affecting Generation of Hortonian Overland Flow in Forested Hillslopes: Analysis of Observation Results at Three Sites with Different Geology and Rainfall Characteristics. 2009 ·Journal of the Japanese Forest Society ·Shusuke Miyata, Yuichi Onda, Takashi Gomi, Shigeru Mizugaki, Hiroaki Asai, (unknown), Taijiro Fukuyama, Ken’ichirou Kosugi, Roy C. Sidle, Tomomi Terajima, Shinya Hiramatsu	12
17	Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy 2009 ·Annals of Oncology ·Daisuke Ennishi, Hiroaki Asai, Yoshinobu Maeda, Katsuji Shinagawa, Kazuma Ikeda, Masaru Yokoyama, Y. Terui, Kengo Takeuchi, T. Yoshino, Keitaro Matsuo, Kiyohiko Hatake, Mitsune Tanimoto	15
18	CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy 2008 ·Annals of Oncology ·Daisuke Ennishi, Kengo Takeuchi, Masaru Yokoyama, Hiroaki Asai, Yuko Mishima, Y. Terui, Shunji Takahashi, Hirotake Komatsu, Kazuma Ikeda, Motoko Yamaguchi, Ritsuro Suzuki, Mitsune Tanimoto, Kiyohiko Hatake	67
19	Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy 2008 ·Annals of Oncology ·Daisuke Ennishi, Masaru Yokoyama, Y. Terui, Hiroaki Asai, Sakura Sakajiri, Yuko Mishima, Shunji Takahashi, Hirotake Komatsu, Kazuma Ikeda, Kengo Takeuchi, Mitsune Tanimoto, Kiyohiko Hatake	46
20	Monoterpenoids from Radermachia sinica 1990 ·Phytochemistry ·Tetsuo Iwagawa, Hiroaki Asai, Tsunao Hase, (unknown), (unknown), Nobuyuki Hagiwara, Mujo Kim	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact